AUTHORS
Hanny Al-Samkari, MD, Laurence Pollissard, MS2, Maria Belen Rodriguez, MD3, Kalyani Hawaldar, MS4, Siddhi Umarje, PharmD, ScM5
AFFILIATIONS
1 Division of Classical Hematology, Mass General Brigham Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
2 Sanofi, Gentilly, France
3 Sanofi, Cambridge, Massachusetts, United States
4 Sanofi, Washington DC, United States
5 Sanofi, Morristown, New Jersey, United States
ABSTRACT
Introduction: Warm autoimmune hemolytic anemia (wAIHA) is a rare autoimmune hematologic disorder driven by complex immune dysregulation, pathogenic autoantibody production and chronic inflammation, leading to substantial disease burden. Beyond anemia-related manifestations, persistent hemolysis, inflammation and immune activation may contribute to major complications, including thromboembolic events (TE) and increased mortality. However, these risks remain incompletely characterized, particularly in treatment-refractory patients. This matched-cohort study quantified TE and mortality risks in a large United States (US) population of newly diagnosed wAIHA patients and within this cohort, in an advanced subcohort, each compared to matched non-wAIHA referent.
Methods: We analyzed STATinMED’s Research Ready Registry, a nationally representative database derived from STATinMED’s RWD insights® (August 2016–October 2023) with Medicaid, Medicare, Medicare Fee-for-Service, Medicare Advantage, and Commercial patients enrolled across the US. We identify 1,642 newly diagnosed primary wAIHA adults, indexed at first observed AIHA/wAIHA diagnosis code, and continuously enrolled for ≥1 year before and after index. Patients with secondary wAIHA, cold agglutinin disease, or mixed AIHA were excluded. Each primary wAIHA patient was matched 1:4 to referent non-wAIHA patients by age, sex, region, insurance type, and index date. An advanced subcohort (n=517), defined by failure of ≥1 wAIHA-directed therapy, was analyzed separately. Arterial and venous TE were identified using published algorithms with prespecified washout and event-aggregation rules; sensitivity analyses assessed the robustness of these definitions. TE rates and Rates Ratio (RR) were adjusted for relevant cardiovascular risk factors and comorbidities and analyzed using quasi-Poisson regression with log link. Mortality was analyzed using Cox proportional hazards models, adjusted for key confounding comorbidities.
Results: The study population had a mean age of 62.3 years; 61.8% were females and mean follow-up was 2.7 years; all patients received at least one wAIHA treatment. Primary wAIHA patients experienced significantly higher incidence of any TE (13.2%) versus matched non-wAIHA patients (5.1%), with adjusted rate (AR) (95% CI): 47.6 (38.2–59.3) vs 24.3 (20.7–28.5) per 1000 person-years (PY) and adjusted rate ratio (aRR) (95% CI): 2.0 (1.6–2.5), p<0.001. Both venous and arterial TE risks were elevated. Venous TE were significantly higher among wAIHA patients: 6.6% vs 1.4%, p<0.001 with AR (95% CI): 25.3 (18.8–34.1) vs 7.3 (5.6–9.6) per 1000 PY; aRR (95% CI): 3.5 (2.4–5.1), p<0.001. The most frequent events were pulmonary embolism: 3.1% vs 0.7%, aRR (95% CI): 3.1 (1.7–5.6), p<0.001 and deep vein thrombosis: 2.8% vs 0.7%, aRR (95% CI): 3.1 (1.9–5.3), p<0.001. Arterial TE were more frequent than venous TE: 7.9% vs 3.9% in wAIHA vs non-wAIHA patients, p<0.001 with AR (95% CI): 26.8 (20.4–35.3) vs 17.3 (14.4–20.9); aRR (95% CI): 1.5 (1.2–2.1), p=0.003. Myocardial infarction was the most frequent arterial event: 3.8% vs 1.1%, aRR (95% CI): 2.6 (1.6–4.5), p<0.001. TE burden was further amplified in treatment-refractory patients: aRR (95% CI): 2.6 (1.7–3.8), p<0.001 for any TE; aRR (95% CI): 4.5 (2.3–8.9), p<0.001 for venous TE; and aRR (95% CI): 2.1 (1.3–3.3), p=0.002 for arterial events. The clinical impact of TE was considerable. Among wAIHA patients with ≥1 TE (n=217), 79.7% required at least one hospitalization (mean 2.4 hospitalizations per patient per year (PPPY), 53.9% required emergency department (ED) care (mean visits 3.6 PPPY) and 94.9% having outpatient encounters (mean 24.2 visits PPPY). Mortality was substantially higher among wAIHA vs non-wAIHA patients:17.6% vs 5.2%, respectively; aRR (95% CI): 2.6 (2.2–3.1), p<0.001.
Conclusions: In this largest matched cohort study of wAIHA to date, we observed substantially elevated thromboembolic and mortality risk in primary wAIHA patients, with even greater risks in advanced wAIHA patients. Among wAIHA patients with thromboembolism, hospitalization represented a substantial clinical burden, alongside significant ED utilization, underscoring the severe impact of these complications. These findings highlight the substantial unmet need in wAIHA and support development of therapies targeting the underlying disease-driving manifestations beyond hemolysis alone.
DISCLOSURES
Hanny Al-Samkari, MD: Atavistik - Research Funding; Sanofi - Research Funding; Amgen - Research Funding; SOBI - Research Funding; Novartis - Research Funding; Alnylam - Research Funding; Vaderis - Research Funding; Tectonic - Research Funding; Argenx - Research Funding; Agios Pharmaceuticals - Research Funding; Alpine Immune Sciences - Research Funding; Pharmacosmos - Research Funding; Novartis - Consultancy (Includes expert testimony); Agios Pharmaceuticals - Consultancy (Includes expert testimony); Alnylam - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Argenx - Consultancy (Includes expert testimony); SOBI - Consultancy (Includes expert testimony); Tectonic - Consultancy (Includes expert testimony); Alpine Immune Sciences - Consultancy (Includes expert testimony); Diagonal - Consultancy (Includes expert testimony); Terremoto - Consultancy (Includes expert testimony); Pharmacosmos - Consultancy (Includes expert testimony); Atavistik - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony)